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Background: In vivo phosphorylation of sphingosine analogs with their ensuing binding and activation of their
cell-surface sphingosine-1-phosphate receptors is regarded as the main immunomodulatory mechanism of this new
class of drugs. Prophylactic treatment with sphingosine analogs interferes with experimental asthma by impeding
the migration of dendritic cells to draining lymph nodes. However, whether these drugs can also alleviate allergic
airway inflammation after its onset remains to be determined. Herein, we investigated to which extent and by
which mechanisms the sphingosine analog AAL-R interferes with key features of asthma in a murine model during
ongoing allergic inflammation induced by Dermatophagoides pteronyssinus.
Methods: BALB/c mice were exposed to either D. pteronyssinus or saline, intranasally, once-daily for 10 consecutive
days. Mice were treated intratracheally with either AAL-R, its pre-phosphorylated form AFD-R, or the vehicle before
every allergen challenge over the last four days, i.e. after the onset of allergic airway inflammation. On day 11, airway
responsiveness to methacholine was measured; inflammatory cells and cytokines were quantified in the airways; and
the numbers and/or viability of T cells, B cells and dendritic cells were assessed in the lungs and draining lymph
nodes.
Results: AAL-R decreased airway hyperresponsiveness induced by D. pteronyssinus by nearly 70%. This was associated
with a strong reduction of IL-5 and IL-13 levels in the airways and with a decreased eosinophilic response. Notably, the
lung CD4+ T cells were almost entirely eliminated by AAL-R, which concurred with enhanced apoptosis/necrosis in that
cell population. This inhibition occurred in the absence of dendritic cell number modulation in draining lymph nodes. On
the other hand, the pre-phosphorylated form AFD-R, which preferentially acts on cell-surface sphingosine-1-phosphate
receptors, was relatively impotent at enhancing cell death, which led to a less efficient control of T cell and eosinophil
responses in the lungs.
(Continued on next page)* Correspondence: David.Marsolais@criucpq.ulaval.ca
1Centre de recherche de l’Institut universitaire de cardiologie et de
pneumologie de Québec (CRIUCPQ), Québec, QC, Canada
3Département de Médecine, Faculté de Médecine, Université Laval, Québec,
QC, Canada
Full list of author information is available at the end of the article
© 2015 Gendron et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Gendron et al. Respiratory Research  (2015) 16:7 Page 2 of 11(Continued from previous page)
Conclusion: Airway delivery of the non-phosphorylated sphingosine analog, but not its pre-phosphorylated counterpart,
is highly efficient at controlling the local T cell response after the onset of allergic airway inflammation. The mechanism
appears to involve local induction of lymphocyte apoptosis/necrosis, while mildly affecting dendritic cell and T cell
accumulation in draining lymph nodes.
Keywords: FTY720, Fingolimod, Gilenya, Dermatophagoides pteronyssinus, Apoptosis, Dendritic cells, CD4+ T cells, Asthma,
S1P, AAL-R, AAL-S, SphingosineBackground
Asthma is a chronic lung disorder with no cure that af-
fects 235 million people worldwide [1]. Asthma de-
creases the quality of life and its yearly cost per country
ranges from 10 to 266 billion dollars [2]. Although a
myriad of interventions exists to alleviate symptoms,
current practices only ensure adequate control of asthma
in less than 50% of patients [3]. Furthermore, up to 10
percent of patients suffer from severe forms of asthma
that are largely refractory to current therapies [4] and
too many still succumb [1]. Given the health and the
economic burden of asthma, identification of new mech-
anisms and targets for intervention is required.
Sphingosine analogs emerge as potent immunomodu-
lators with therapeutic efficacy proven in humans. For
instance, the drug FTY720 (Fingolimod, Gilenya) is cur-
rently used for patients with multiple sclerosis [5]. The
compound AAL-R is an analog of FTY720 that has been
broadly used to study the mechanisms of action of this
class of compounds [6-9]. Sphingosine analogs such as
FTY720 and AAL-R are cell-permeant and become
phosphorylated intracellularly to become a sphingosine-
1-phosphate (S1P) analog. They are then actively
exported from the cells. Owing to their phosphorylation,
the secreted forms of the drugs are cell-impermeant and
their mechanisms of action become then restricted to
extracellular effects, which are mediated by binding on
four of the five cell surface S1P receptors (S1P1,3–5) [8].
The archetypal mechanism of action of sphingosine ana-
logs is sequestration of lymphocytes in secondary lymph-
oid organs after activation of S1P1 [10]. However, it is
increasingly recognized that activation of S1P receptors
following the intracellular phosphorylation and secretion
of the analogs is not the only mechanism underlying
their bioactivity. These compounds can indeed modulate
cellular functions independently of S1P receptor engage-
ment, including among others cell fate and the activity of
both phospholipase and phosphatase subsets [6,11,12].
The mechanisms of action of sphingosine analogs are thus
complex, misunderstood, and might vary under different
pathophysiological conditions.
When administered in a prophylactic fashion, phos-
phorylatable sphingosine analogs interfere with the de-
velopment of experimental allergic airway inflammation.This was demonstrated in the classical model induced
by systemic sensitization with ovalbumin (OVA) emulsi-
fied in aluminum (Alum), followed by airway challenges
with OVA (OVA-Alum model) [13]. The mechanism of
action under these conditions is potent inhibition of
dendritic cell (DC) accumulation in draining lymph
nodes, interference with antigen presentation, and failure
to launch an efficient antigen-specific T cell response
[13,14]. However, whether the phosphorylatable sphingo-
sine analogs are salutary when administered in a thera-
peutic fashion, i.e. after the onset of allergic airway
inflammation, is undefined. Additionally, the efficacy of
phosphorylatable sphingosine analogs to interfere with air-
way inflammation induced by a natural allergen has never
been studied. In contrast with the classical OVA-Alum
model, natural allergens have specific modi operandi – in-
cluding proteolytic activity and endogenous adjuvant ac-
tivity [15]. Importantly, the natural allergens evoke a
classical allergic response by local mechanisms involving
pulmonary DC when delivered through natural routes of
exposure, such as the airways [16]. They thus recapitulate
more genuinely the mechanisms of allergic airway inflam-
mation in humans.
Under these premises, we aimed to determine if a
sphingosine analog, namely AAL-R, alleviates experi-
mental asthma elicited by subchronic airway inflamma-
tion induced by exposure to a natural allergen, namely
Dermatophagoides pteronyssinus (house dust mite ex-
tract; HDM). We hypothesized that treatment with
AAL-R after the onset of HDM-induced airway inflam-
mation interferes with mechanisms leading to key fea-
tures of asthma in a murine model.Methods
Murine model of asthma
Pathogen-free BALB/c female mice (8 weeks old, Charles
River) were anesthetized with isoflurane and instilled in-
tranasally (i.n.) with 50 μl of saline or with saline con-
taining 50 or 75 μg HDM extract (Greer), once daily,
from day 1 to 10. Unless otherwise indicated, all mea-
surements were taken at day 11. The mice were either
euthanized with ketamine-xylazine overdose for collec-
tion of the bronchoalveolar lavage fluid (BALF) and for
tissue sampling; or tested for airway responsiveness to
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perimental, housing and care procedures were approved
by the Committee of Animal Care of Laval University in
accordance with the guidelines of the Canadian Council
on Animal Care (protocols 2013037, 2009128).Immunoglobulin titration
Plates were coated with 50 μg/mL HDM and incubated
with serial dilution of serum (1:200 to 1:145800). Titers were
determined by a colorimetric reaction as reported [18].Experimental treatments
Naïve or HDM-instilled mice were treated intratrache-
ally (i.t.) with either 50 μl of distilled water (dH2O) con-
taining 2.5 μg of AAL-R, or the vehicle (dH2O) from day
7 to day 10. This dose, which corresponds to 0.1 mg/kg,
was chosen because it does not induce histological alter-
ations per se, and because it was shown to potently induce
immunomodulation in the airways [13,14]. Treatments
were delivered under isoflurane anesthesia and animals
were thereafter placed in standard housing conditions for
1 h until re-anesthesized with isoflurane prior to HDM in-
stillation. In a second series of experiments, an additional
group was treated with a molar equivalent dose (3.5 μg) of
the phosphorylated sphingosine analog, namely AFD-R.
Compounds were either provided by Dr Hugh Rosen
(TSRI) or synthetized using a modification of published
methods (NuChem Therapeutics Inc.) [19,20].Differential counts, flow cytometric analyses and
quantification of cytokines
BALF as well as single-cell suspensions from both the
right and central lobes and from draining mediastinal
lymph nodes (MLN) were obtained as previously re-
ported [21]. Antibodies are anti- CD4 (RM4-5)
(eBioscience); CD8a (53–6.7), CD11c (N418), CD19
(6D5), CD90.2 (30-H12), Ki-67 (16A8) (Biolegend);
MHC-II (2G9) (BD Biosciences). Viability was assessed
using annexin V (Biolegend) and LIVE/DEAD (Life
Technologies). Fluorescence and autofluorescence (AF)
were acquired using a Diva-driven LSRFortessa (Becton
Dickinson) and analyzed with the FlowJo software (Tree
Star inc). To compute the total numbers of cell subsets,
absolute cell counts obtained with a hemocytometer
were multiplied by cell frequencies obtained either by
flow cytometry or following differential cell counts as
previously reported [17,21]. For cytokine quantification,
cell-free BALF were concentrated with Amicon 3 K
(Millipore) and incubated with cytometric bead array
Flex Set for interleukin (IL)-5, IL-13 and CCL5 accord-
ing to the manufacturer’s instructions (BD Biosciences).Histology
After BALF were performed, the left caudal lobes were
processed as previously described [18] and stained with
either hematoxylin and eosin (H&E) for the evaluation
of inflammatory cell infiltrate; or with Periodic Acid-
Schiff (PAS) stain and hematoxylin for the evaluation of
mucus-producing cells. Histological evaluation was per-
formed by an American College of Veterinary Pathologists
Board-certified pathologist (CT). The nomenclature used
to describe the lesion and the severity of the lesions (5
grades scale) was based on the guidelines provided by the
Society of Toxicological Pathology [22,23].
Measurement of airway responsiveness
Methacholine (MCh) challenge test was performed on
tracheotomized mice connected to a flexiVent apparatus
(SCIREQ) as previously reported [17].
Statistical analyses
Unless otherwise stated, the data shown are means ±
SEM. Data were analyzed using one-way ANOVAs. To
fulfill the normality and variance assumptions, variables
were log-transformed. An arc sinus transformation on
the square root was applied on BALF measurements that
were expressed in percentage. Homogeneity of covari-
ance parameter assumption among groups was verified.
A posteriori comparisons were performed with Tukey’s
comparison technique. All reported P values are based
on these transformations. In addition, the nonparametric
Kruskal-Wallis test was performed on histology data.
The results were considered significant with p values ≤
0.05, unless otherwise stated. All analyses were conducted
using the statistical package SAS v9.3 (SAS Institute Inc).
Results
Onset of allergic airway inflammation in response to daily
exposure to HDM
In order to ensure that our experimental treatments
were undertaken after the inception of local allergic in-
flammation, we assessed the kinetics of the systemic and
the local allergic responses in this subchronic model in-
duced by HDM. Inflammation was evaluated in the
BALF at day 4, 7, and 11. Daily i.n. delivery of saline
failed to induce accumulation of leukocytes in the BALF
(Figure 1). In contrast, HDM delivery was associated
with a mild increase of absolute numbers of lymphocytes
(0.22 ± 0.02 × 105, Figure 1A) and neutrophils (0.29 ±
0.08 × 105, Figure 1B) in BALF on day 4. Instillation of
HDM also induced the recruitment of eosinophils in the
airways with 0.18 ± 0.07 × 105 eosinophils in BALF at
day 7 (Figure 1C). The number of eosinophils reached
2.0 ± 0.6 × 105 at day 11. The appearance of antigen-
specific IgG1 (functional equivalent to human IgE) in
serum (Figure 1D) coincided with the onset of
A B
C D
Figure 1 The onset of allergic inflammation is established at day 7. Mice received HDM (□) or saline (SAL) (◊) i.n. once-daily for 0, 3, 6 or 10 days
and were then euthanized 24 h after the last exposure. BALF were performed and differential cell counts were determined for A) lymphocytes, B) neutrophils,
and C) eosinophils. D) Serum HDM-specific IgG1 titers were also quantified. n = 4 per group and *indicates significant differences in corresponding days
between SAL- and HDM-exposed mice. P <0.05 N.D.: not detected.
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that time-point. These results indicated that the onset of
allergic airway inflammation was clearly established at day
7 and it was thus a proper time for initiating the treatment
with sphingosine analogs (Figure 2).
AAL-R alleviates airway responsiveness induced by HDM
In patients with allergic asthma, the sensitization phase
has already occurred and exacerbations arise due toFigure 2 Experimental design. Mice were instilled i.n. with HDM or saline (
vehicle (dH2O) or dH2O containing 2.5 μg of AAL-R from day 7 to day 10, one
AFD-R (molar equivalent of AAL-R) were used instead of AAL-R. 24 h after the
tissue sampling or tested to assess their degree of airway responsiveness to Minflammatory flares triggered by allergen exposures. To be
physiologically meaningful, a treatment may thus be able
to alleviate pathognomonic features of asthma after its on-
set. We first determined whether local delivery of AAL-R
after the onset of allergic airway inflammation interferes
with alteration of respiratory function (Figure 3A). Mice
treated daily with saline showed a weak increase of re-
spiratory system resistance (Rrs) in response to MCh with
a delta of 7.1 ± 1.1 cmH2O/mL/s between baseline (0.4SAL) from day 1 to 10, along which time they were also treated i.t. with
hour before HDM administration. In a subset of experiments, 3.5 μg of
last exposure, mice were either euthanized for the collection of BALF and
Ch.
Figure 3 (See legend on next page.)
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Figure 3 AAL-R interferes with hallmarks of asthma induced by HDM. A) The degree of airway responsiveness was assessed by monitoring
the change of respiratory system resistance (Rrs) during doubling doses of MCh. Paraffin-embedded tissue sections of lung stained with either
H&E to assess B) inflammatory infiltrates in the peribronchial/perivascular regions or C) PAS to label mucus-producing cells. n = 4–5 mice per
group and *indicates significant differences P <0.05. bar = 150 μm.
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HDM showed a dose-dependent increase of Rrs that
reached 26.9 ± 4.3 cmH2O/mL/s at the highest MCh dose.
In saline-treated mice, AAL-R did not modulate Rrs in re-
sponse to MCh. On the other hand, AAL-R inhibited
HDM-induced airway hyperresponsiveness by as much as
70% at doses of 0.25 and 0.5 mg/kg of MCh. The func-
tional advantage provided by AAL-R was associated with
amelioration of histological features. For instance, AAL-R
decreased median perivascular and peribronchial accumu-
lation of mononuclear cells (Figure 3B; Table 1) as well as
HDM-associated alteration of the epithelium, including
PAS reactivity and epithelial layer hypertrophy (Figure 3C,
Table 1). Thus, treatment with AAL-R inhibits functional
and histological alterations caused by HDM instillation.
AAL-R interferes with lung accumulation of cells that
drive inflammation induced by HDM
We then set out to investigate whether and by which
mechanisms AAL-R affects the ongoing inflammatory
response to HDM in the lungs. The effect of AAL-R on
the leukocyte profile in the BALF was first investigated
(Figure 4). AAL-R had no drastic effect on numbers of
leukocytes in the group receiving saline instead of HDM.
The absolute number of leukocytes decreased from 5.6 ±
0.8 × 105 in vehicle-treated HDM mice to 2.6 ± 0.4 × 105
in AAL-R-treated HDM mice (Figure 4A). In mice receiv-
ing saline, AAL-R did not affect the proportion of different
cell subsets in the BALF (Figure 4B). No eosinophilia was
detected in the saline groups and the percentage of eosin-
ophils was increased to 43 ± 12 by HDM, which was re-
duced to 14 ± 3 with AAL-R (Figure 4B). This resulted in
an absolute decrease of eosinophil number in the BALF
(Figure 4C). In cell suspensions prepared from the lungs,
AAL-R decreased AFneg CD11chi MHCIIhi DC numbers
by more than 50% in mice exposed to HDM (Figure 4D),
which was accompanied by a 90% decrease of pulmonaryTable 1 Histopathological alterations of mice lungs exposed t
Sa
Treatments VE
Perivascular infiltration of mononuclear cells 0
Peribronchial/bronchiolar infiltration of mononuclear cells 0
Perivascular infiltration of granulocytes 0
Hypertrophy/hyperplasia of the bronchial epithelium 0
Results are expressed as median scores for each group, graded on a scale from 0 (n
4–5 mice per group were analyzed. *P < 0.001 between HDM and Saline; †P < 0.01 bCD4+ T cells (Figure 4E) and by a 70% decrease of pul-
monary CD19+ B cells (Figure 4F), when compared with
the vehicle-treated HDM-exposed group. The decrease in
lymphocyte numbers in AAL-R-treated mice also occurs
in conjunction with a decrease in lymphocyte-secreted cy-
tokines IL-5 and IL-13 (Figure 4G-H), while having no ef-
fect on CCL5, a chemokine predominantly secreted by
epithelial cells (Figure 4I). These results support the effi-
cacy of locally-delivered AAL-R to interfere with accumu-
lation of cells critically involved in the immunopathological
responses seen in allergic asthma.
AAL-R enhances apoptosis/necrosis of lymphocytes in the
lung
Although a rich literature supports sphingosine analogs
to induce apoptosis, whether or not this mechanism is
involved in the decrease of leukocyte numbers in the
lungs remains undetermined. As previously reported
[24] apoptotic/necrotic lymphocytes were detected in
the lungs under basal conditions (Figure 5). The per-
centage of annexin V+ CD4+ T cells changed from 13.3
± 1.3 in vehicle-treated HDM-exposed mice to 24.6 ± 1.6
in HDM-exposed mice treated with AAL-R (Figure 5A).
Similarly, the proportion of CD19+ B cells positive for
annexin V increased by 27.9% in AAL-R-treated mice
(Figure 5A). Weak to null apoptosis/necrosis was in-
duced in both CD8+ T cells and the CD90−CD19−AF
−SSCmed-hi granulocyte-enriched fraction (not shown),
supporting cell type-specific induction of cell death in
the lungs. In contrast, a molar equivalent dose of the
phosphorylated AAL-R analog, AFD-R, failed to induce
potent apoptosis/necrosis of CD4+ T cells and CD19+ B
cells, when compared with the vehicle-treated HDM-
exposed group. Notably, AFD-R was less efficient than
AAL-R to interfere with the T cell and B cell responses in
the airways (Figure 5B-C), when compared with AAL-R.
Accordingly, AFD-R was also less efficient than AAL-R too HDM
line HDM
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Figure 4 AAL-R inhibits allergic airway inflammation. BALF was assessed to determine: A) the total number of cells; B) the differential count of
cells; and C) the total number of eosinophils. Inflammation was also assessed in single-cell suspensions derived from digested lungs to determine: D) The
total number of AFneg MHC-IIhi CD11chi DC; E) the number of lung AFneg SSClow CD90.2+ CD8neg CD4+ T cells; and F) the number of lung AFneg SSClow
CD90.2neg CD19+ B cells. Levels of G) IL-5, H) IL-13, and I) CCL5 were also quantified in BALF. Shown is representative of two independent experiments.
n = 4–5 per group and *signifies significant differences at P <0.05 (#P = 0.07).
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phosphorylatable sphingosine analog, but not its pre-
phosphorylated form, potently induces death of cell sub-
sets that are central to allergic airway inflammation.
Effect of intratracheal delivery of AAL-R on lymphocytes
and DC in the draining lymph nodes
We next addressed the ability of AAL-R delivered into the
lungs to interfere with the biology of draining MLNs.
Compared with vehicle-treated mice with experimental
asthma, AAL-R mildly reduced CD4+ T lymphocyte num-
bers in the MLNs (Figure 6A) and failed to modulateCD19+ B cell and DC numbers in this compartment
(Figure 6B-C). This is in agreement with the lack of effect
on the frequency of proliferative Ki67+ CD4+ T cells
(Figure 6D). AAL-R also failed to modulate the percentage
of annexin V+ CD4+ cells and annexin V+ CD19+ cells in
MLNs (Figure 6E-F). In contrast, AFD-R increased the
numbers of CD4+ T cells in MLNs by 85 %; albeit equally
ineffective as AAL-R to alter DC numbers. Thus, on one
hand, it appears that AAL-R acts directly in the lungs
without affecting leukocyte numbers in the draining
lymph nodes. On the other hand, the pre-phosphorylated
form (AFD-R) seems to preferentially attenuate cell
Figure 5 AAL-R increases lymphocyte apoptosis/necrosis in the lungs. Single-cell suspensions were obtained from the lungs to determine:
A) the frequency of apoptotic/necrotic annexin V+ cells in two subpopulations of cells, namely AFneg SSClow CD90.2+ CD8neg CD4+ T cells (upper
panels) and AFneg SSClow CD90.2neg CD19+ B cells (lower panels); B) the number of CD4+ T cells; and C) the number of CD19+ B cells in the lung.
Total number of eosinophils was also determined in the BALF (D). Shown is representative of two independent experiments. n = 6–8 mice per
group and *indicates significant differences versus VEH; §indicates significant differences versus AAL-R. P <0.05.
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draining lymph nodes.Discussion
Sphingosine analogs are new therapeutic molecules with
potent immunomodulatory properties. Yet, their poten-
tial in the treatment of asthma is misunderstood. The
main finding of this study is the efficacy of a phosphory-
latable sphingosine analog to interfere with asthma in a
murine model after the onset of allergic inflammationinduced by a natural allergen. We also reveal that
lymphocyte and DC numbers in draining lymph nodes
are not modulated by AAL-R, as it was previously ob-
served in the OVA-Alum model of asthma [14]. Con-
versely, AAL-R attenuates the accumulation of
eosinophils, DC, CD4+ T cells and CD19+ B cells in the
lungs. This was associated with significant decreases of
IL-5 and IL-13 levels in the BALF. We also identify the
induction of T cell apoptosis as a significant mechanism
contributing to the alleviation of allergic airway inflam-
mation by AAL-R; and this phenomenon was not
Figure 6 Effects of non- or pre-phosphorylated analogs in draining lymph nodes. Single-cell suspensions derived from MLNs were obtained
to determine: A) the total number of AFneg SSClow CD90.2+ CD8neg CD4+ T cells; B) the total number of AFneg SSClow CD90.2neg CD19+ B cells; C) the
total number of MHC-IIhi CD11chi DC; D) the frequency of Ki67+ CD4+ T cells; E) the frequency of apoptotic/necrotic CD4+ T cells; and F) the frequency
of apoptotic/necrotic CD19+ B cells. Apoptosis and proliferation could not be evaluated in saline mice given the paucity of cells. n = 6–8 mice per
group and *signifies significant differences P <0.05. For panels A to C, means of all experimental groups are statistically different from SAL. Shown is
representative of two independent experiments.
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form of the drug.
Previous studies have addressed the roles of S1P path-
way modifiers in the phase of intra peritoneal
sensitization with OVA-Alum [25]. In addition, adminis-
tration of S1P pathway modifiers prior to, or concomi-
tantly with, repetitive OVA challenges in peripherally
sensitized animals was shown to be effective in prevent-
ing cardinal features of experimental asthma [14]. How-
ever, it was heretofore unknown whether the drugs were
able to attenuate key features of established allergic air-
way inflammation. The findings of the present study rep-
resent the first evidence that a phosphorylatable
sphingosine analog can alleviate experimental asthma
after the onset of allergic airway inflammation.
It is becoming clear that the airway mucosa can be a
critical site for amplification and maintenance of allergic
disease [26]. Consequently, models using natural aller-
gens that cause signs of experimental asthma when de-
livered through natural routes are currently preferred to
assess the preclinical potential of experimental treat-
ments [27]. In the model used herein, airway delivery of
HDM was sufficient to trigger functional impairment of
the airways, accumulation of T cells, B cells andeosinophils. Remarkably, all of which were inhibited by
AAL-R. In accordance with our current finding, FTY720
dampens eosinophil accumulation within the mucosa in
a model of ongoing allergic rhinitis [28]. Unfortunately,
the number of DC in draining lymphoid tissues was not
assessed in that latter study [28]. In our study, both local
DC and T cells were severely altered by local treatment
with AAL-R, which is a major interest owing to the pre-
dominant role played by these cell subsets in pulmonary
inflammation. This alteration of the local T cell response
was also associated with a strong decrease of IL-5 and
IL-13 levels in the airways. Of potential importance is
the fact that these interleukins can by themselves in-
crease the contractile capacity of airway smooth muscle
[29]. It is thus likely that AAL-R interfered with airway
hyperresponsiveness, at least in part, by reducing the
levels of soluble factors that potentiate the contractile
capacity of airway smooth muscle. On note, airway
smooth muscle enlargement is not observed in this acute
model; so impairment of this feature may not be related
to the beneficial effect of AAL-R on airway hyperrespon-
siveness. The location of T cells has also recently
emerged as a critical mechanism influencing the con-
tractile capacity of airway smooth muscle. Indeed, T cells
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tractile capacity [30,31]. It is tempting to speculate that
the profound reduction of T cell numbers by AAL-R
might have contributed to alleviate hyperresponsiveness
by reducing the number of T cells located proximally to
the contractile apparatus of the airways.
The current work also highlights that the immuno-
modulatory mechanisms of sphingosine analogs after the
onset of allergic inflammation likely differ from the ones
observed in the context of a prophylactic treatment.
When administered prophylactically, i.e. prior to airway
OVA challenge, sphingosine analogs strongly inhibit
antigen presentation in draining lymph nodes, which is
responsible for the alleviation of experimental allergic
airway disease [13,14]. In agreement with these results,
airway delivery of a single dose of AAL-R soon after in-
fluenza virus infection inhibits both DC accumulation in
draining lymph nodes and the ensuing immunopatho-
logical responses in the airways [9,32]. Conversely, our
results show that AAL-R strongly inhibits DC accumula-
tion in the lungs while having mild effects on DC num-
bers in MLNs over the course of a 4-day treatment.
These results are in line with the ability of sphingosine
analogs to interfere with de novo DC recruitment from
blood to tissues [33], and to blunt the release of chemo-
tactic factors in the lung [9,13]. While we cannot fully
exclude the possibility that antigen presentation was
modulated, our results rather suggest that once DCs
have migrated to the lymph node, sphingosine analogs
are relatively impotent at interfering with the chain of
events leading to the antigen-triggered amplification of
lymphocytes.
Although several studies used local delivery of sphingo-
sine analogs [9,13,14,21,34,35], and sphingosine analogs are
well known inducers of cell death [11], this is the first evi-
dence supporting the idea that cell death could contribute
to alleviate allergic airway disease. Indeed, aminoalcohols
like AAL-R readily penetrate the plasma membrane and be-
come phosphorylated intracellularly to interfere with cell
survival [11]. Accordingly, we show that AAL-R, but not
AFD-R, potently induces lymphocyte apoptosis/necrosis in
the lung. This is consistent with AAL-R’s rapid phosphoryl-
ation, low turnover, and potent induction of apoptosis in
murine splenocytes through intracellular accumulation of
AFD-R [7]. Interestingly, AAL-R-induced apoptosis/necro-
sis appears to affect CD4+ T cells and B cells, which are
crucially involved in allergic airway disease, while having no
effect on CD8+ T cells, DCs and the CD90−CD19−AF
−SSCmed-hi granulocyte-enriched fraction. These results cer-
tainly argue against a non-specific toxic effect. Of note,
FTY720 was associated with preferential apoptosis of acti-
vated T cells in another model [36], while not potently af-
fecting DC apoptosis in vitro [37] and myeloid leukocyte
apoptosis in vivo [38]. In a preclinical perspective, drugsthat are customarily used to treat asthma can induce apop-
tosis in cells from the airways, supporting the viability of
this drug-related mechanism of action in humans [39,40].
Lymphopenia has long been associated with the im-
munomodulatory effects of sphingosine analogs. Yet, a
number of facts challenge the idea that systemic lym-
phopenia per se is central to immunomodulation. In-
deed, local treatments with sphingosine analogs induce
more potent immunosuppression than systemic delivery
[9]. In addition, naïve T cells are more sensitive to
sphingosine analogs-induced lymphopenia than activated
T cells [41]. Our results reveal that distinct mechanisms of
action could be associated with the non-phosphorylated
and the phosphorylated forms of the compounds. Specific-
ally, our results demonstrated that AAL-R induces a more
severe local T cell inhibition than AFD-R, which correlates
with the ability of AAL-R to induce local death of lympho-
cytes. The idea that lymphopenia-independent mecha-
nisms could explain, at least in part, the local
immunosuppression induced by sphingosine analogs is
also supported by the observation that prophylactic treat-
ment with the non-phosphorylatable AAL-S enantiomer,
yet at a somewhat superior dosage than in the current
study, inhibits cytokine release as well as T cell and DC ac-
cumulation in the airways in a model of experimental
asthma [6]. This effect was associated with activation of
protein phosphatase 2A, but it remains unknown if such
mechanism is viable under the current conditions.
Conclusion
We conclude that a phosphorylatable sphingosine ana-
log can interfere with allergic airway inflammation
caused by a natural allergen, resulting in improved re-
spiratory function. The mechanism of action appears to
differ from that previously observed in a prophylactic
context. Our results also support that the phosphoryl-
ation status of the drug can influence the mechanisms
by which the immune response is modulated, with en-
hancement of T cell apoptosis being restricted to the
non-phosphorylated form.
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